

## SUPPLEMENTARY DATA

**Supplementary Figure S1:** Talazoparib inhibition of PBMC PARP activity. The change in percentage baseline PBMC PARP activity during cycle 1 of Part 1 is presented in the Figure below. During the single-dose assessment period, onset of inhibition was rapid (by the 2-hour postdose assessment) and persisted through at least cycle 1 day 2, or approximately 24 hours postdose (data not shown). During the multiple-dose assessment period, consistent PARP inhibition was observed in all but one patient at dose levels 0.6 mg/day and above. During the washout period following dosing on day 35, PARP inhibition persisted in all patients at 0.6 mg/day and above through 24 hours postdose and in many patients through 96 hours postdose. Abbreviations: PARP, poly(ADP-ribose) polymerase; PBMC, peripheral blood mononuclear cell.

